{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 56,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 9,
  "notes": "The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/16",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.21
      },
      "kind": "chart",
      "text": "UC Maintenance Efficacy Pbo-adjusted clinical remission %",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6777e83-31dc-4f78-9cbf-73ec5687fdc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.03,
        "y": 0.33
      },
      "kind": "list",
      "text": "Vedolizumab specifically binds α4β7 integrin, selectively blocking gut lymphocyte trafficking. Leading maintenance efficacy data in UC replicated in two P3 studies; efficacy on par with upadacitinib 15mg dose; superior head-to-head vs adalimumab (Humira) in UC. Clean safety profile since approval in 2014. #1 biologic in IBD bio-naïve patients in the US.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8e3239a-eccf-410b-9e4f-93e39bc69bef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "quote",
      "text": "“Entyvio (vedolizumab) is the safest drug and one of the most effective for UC.” – US KOL",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fd9f929-9f55-425f-aae8-879455f6f501",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "1. Takeda JPM 2023 presentation. Figure data sources: Vedolizumab IV and SC data from VISIBLE 1 P3 study. Ustekinumab, adalimumab, infliximab, golimumab, ozanimod, tofacitinib, upadacitinib data from labels. Mirikizumab data from phase 3 LUCENT-2 study.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14f48b1e-6514-489a-8f21-bc4058fc90d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Vedolizumab maintenance efficacy and exquisite safety make it preferred biologic in moderate-to-severe UC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fda50922-a8e1-458e-9f90-02938754cba8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "7bef0963-153d-4e2c-ae7c-ea8654f92ab0",
      "evidence": "Compares efficacy and safety of multiple drugs in a single chart.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 13,
      "beatId": "5fcb9464-3068-4031-9434-ce301bbe9fd3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents the company's solution, including its pipeline and strategy",
      "position": 3,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1d2b0809-4269-4aea-a725-b67c9452d570",
      "evidence": "The document presents the company's solution, including its pipeline and strategy",
      "position": 2,
      "objective": "What is the company's solution?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}